mullokintyre Posted December 10, 2020 Share Posted December 10, 2020 A bit surprised this news did not make a bigger splash in MSM. 'FromYAhoo and Bloombergs The federal government has canned a deal to buy tens of millions of doses of a potential coronavirus vaccine being developed in Australia. The decision was made after the University of Queensland and biotechnology company CSL abandoned trials of their COVID-19 vaccine candidate. CSL said in a statement that while phase 1 trials of the vaccine v451 amongst 216 participants showed it was safe, it had "following agreement with the Australian government" decided not to progress the trials. The trials were abandoned after some participants returned false positive results for another illness - HIV. "The phase 1 data showed the generation of antibodies directed towards the 'molecular clamp' component of the vaccine," CSL said on Friday. "These antibodies interfere with certain HIV diagnostic assays. CSL said blood samples from study participants were tested after vaccination and it was found that these molecular clamp antibodies did cause a false positive. "Follow up tests confirmed that there was no HIV virus present, just a false positive on certain HIV tests," CSL said. "There is no possibility the vaccine causes infection." Won't help OZ or CSL's share price. Mick Link to comment Share on other sites More sharing options...
nipper Posted January 7, 2021 Share Posted January 7, 2021 CSL Limited (ASX:CSL) Nominated by Gemma Dale, nabtrade Despite being Australia’s largest company and having delivered exceptional outperformance relative to the ASX200 over the last two decades, CSL is not very widely held among retail investors on nabtrade. Just 5.5% of investors hold the stock directly. Those who do hold CSL, however, own over $100,000 on average, over 4x the average stock holding, so it is a very high conviction investment. The lack of allocation to CSL is usually a result of concerns about its relatively small dividend yield (1%), or valuation (CSL is currently trading on a forward PE of about 42x). The attraction for those who hold it is the extraordinary growth of earnings relative to other large companies. For those who have ever considered buying CSL, now doesn’t appear to be a bad time. Having taken a hit on the back of the cessation of its UQ-led Covid19 vaccination trial, at $290 at the time of writing, CSL is up just 18% from its lows in March. This is well below the market’s return of nearly 50% from its lows. CSL remains well off its highs of $342 and management maintains that Covid trial was not material to its current valuation, meaning the recent pull back could be a happy buying opportunity. Nabtrade investors seem to think so. ... it has topped the trading with a 90% buy over three days since the trial was cancelled. Link to comment Share on other sites More sharing options...
nipper Posted February 11, 2021 Share Posted February 11, 2021 Inside CSL, where Australia's Oxford-AstraZeneca vaccines are being made https://www.abc.net.au/news/science/2021-02...turing/13140104 It is an interesting read.... & I have always had the view that CSL was not going to gain much from making the vaccine, apart from being a good .corporate citizen. (oh, and being in the prime position for future work) Link to comment Share on other sites More sharing options...
mullokintyre Posted February 17, 2021 Share Posted February 17, 2021 Half yearly out, makes reasonable reading under the covid circumstances. Most important, Div's reduced a bit due to the increase in AUDvUSD, but that was always on the cards. Market seems to like it, up another 3% post announcement. mick Link to comment Share on other sites More sharing options...
nipper Posted February 17, 2021 Share Posted February 17, 2021 yep .... looks like a good result Interim dividend of US$1.04 per share, up 9% ... Converted to Australian currency, the interim dividend is approximately A$1.34 per share down 9%. Link to comment Share on other sites More sharing options...
plastic Posted February 18, 2021 Share Posted February 18, 2021 Merck looks wounded by Covid. Could be a takeover target for CSL. Link to comment Share on other sites More sharing options...
mullokintyre Posted February 18, 2021 Share Posted February 18, 2021 Merck looks wounded by Covid. Could be a takeover target for CSL. But why would they bother? What are the synergies? What part of the CSL business will it bolster? Mick Link to comment Share on other sites More sharing options...
plastic Posted February 18, 2021 Share Posted February 18, 2021 You are way smarter than that. Could be a little while yet though. Link to comment Share on other sites More sharing options...
mullokintyre Posted February 18, 2021 Share Posted February 18, 2021 Flattery will get you nowhere. Why not just answer one of the questions I posed. Theres more chance of Apple taking over Merck than CSL doing so. This sub topic would have been more appropriate in "plastics Conspiracy Theories".. Mick Link to comment Share on other sites More sharing options...
plastic Posted February 18, 2021 Share Posted February 18, 2021 You are clearly ignorant of the long and profitable tenure Merck has enjoyed with Au. biotech. Its not for me to explain it. Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now